Relapse rate following withdrawal of vedolizumab and ustekinumab in patients with inflammatory bowel disease - a multicenter retrospective controlled study. The VEDUST-EXIT Study.

Albshesh A, Kucha P, Pugliese D, Amiot A, Mahajna H, Eder P, Savarino EV, Vavricka S, Castiglione F, Imperatore N, Krznaric Z, Abitbol CM, Hen O, Zaborowska M, Carbonnel F, Cuccia G, Lorenzon G, Zittan E, Zagórowicz E, Maniero D, Ben-Horin S, Kopylov U

Open source

DOI: 10.1016/j.dld.2025.09.032
Published: 2025 Dec
Container: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.dld.2025.09.032,
  title = {Relapse rate following withdrawal of vedolizumab and ustekinumab in patients with inflammatory bowel disease - a multicenter retrospective controlled study. The VEDUST-EXIT Study.},
  author = {Albshesh A and Kucha P and Pugliese D and Amiot A and Mahajna H and Eder P and Savarino EV and Vavricka S and Castiglione F and Imperatore N and Krznaric Z and Abitbol CM and Hen O and Zaborowska M and Carbonnel F and Cuccia G and Lorenzon G and Zittan E and Zagórowicz E and Maniero D and Ben-Horin S and Kopylov U},
  year = {2025},
  journal = {Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver},
  doi = {10.1016/j.dld.2025.09.032},
  url = {https://doi.org/10.1016/j.dld.2025.09.032}
}

RIS

TY  - JOUR
TI  - Relapse rate following withdrawal of vedolizumab and ustekinumab in patients with inflammatory bowel disease - a multicenter retrospective controlled study. The VEDUST-EXIT Study.
AU  - Albshesh A
AU  - Kucha P
AU  - Pugliese D
AU  - Amiot A
AU  - Mahajna H
AU  - Eder P
AU  - Savarino EV
AU  - Vavricka S
AU  - Castiglione F
AU  - Imperatore N
AU  - Krznaric Z
AU  - Abitbol CM
AU  - Hen O
AU  - Zaborowska M
AU  - Carbonnel F
AU  - Cuccia G
AU  - Lorenzon G
AU  - Zittan E
AU  - Zagórowicz E
AU  - Maniero D
AU  - Ben-Horin S
AU  - Kopylov U
PY  - 2025
JO  - Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
DO  - 10.1016/j.dld.2025.09.032
UR  - https://doi.org/10.1016/j.dld.2025.09.032
ER  -

APA

A, A., P, K., D, P., A, A., H, M., P, E., EV, S., S, V., F, C., N, I., Z, K., CM, A., O, H., M, Z., F, C., G, C., G, L., E, Z., E, Z., D, M., S, B., & U, K. (2025). Relapse rate following withdrawal of vedolizumab and ustekinumab in patients with inflammatory bowel disease - a multicenter retrospective controlled study. The VEDUST-EXIT Study.. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. https://doi.org/10.1016/j.dld.2025.09.032

Source records

pubmed · retrieved 2026-09-26T05:37:59.647Z